Welcome to our dedicated page for Mainz Biomed NV SEC filings (Ticker: MYNZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mainz Biomed N.V. (NASDAQ: MYNZ) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a foreign private issuer, alongside AI‑generated explanations to help interpret them. Mainz Biomed is a molecular genetics diagnostic company specializing in early cancer detection, and its filings provide detail on capital raising activities, share capital structure, and periodic financial reporting.
Recent Form 6‑K reports describe key financing arrangements, such as a Securities Purchase Agreement for the sale of pre‑funded units that include pre‑funded warrants and ordinary warrants, and a Placement Agency Agreement with Maxim Group LLC. Another 6‑K outlines an Equity Distribution Agreement that allows the company to sell ordinary shares through at‑the‑market offerings on the Nasdaq Capital Market or other permitted venues, with information on commission rates, offering limits, and the role of the sales agent.
Filings also cover corporate governance and share capital changes. A Deed of Amendment to the Articles of Association, reported on Form 6‑K, details adjustments to the nominal value of ordinary and preferred shares, an increase in authorized share capital within specified limits, and the elimination of fractional shares. Additional 6‑K reports make available the Management’s Discussion and Analysis of Financial Condition and Results of Operations and unaudited financial statements for defined periods, along with associated Inline XBRL data.
On this page, users can access these documents as they are furnished to the U.S. Securities and Exchange Commission through EDGAR. AI‑powered summaries highlight the main points of lengthy filings, explain the implications of capital markets transactions, and point out where financial statements and management commentary can be found. Investors can also monitor how equity distribution programs, warrant offerings, and amendments to share capital may affect the company’s capital structure over time, all within a single, organized view of Mainz Biomed’s SEC reporting history.
Mainz Biomed director David E. Lazar reported a major preferred share investment. On February 13, 2026, he entered a securities purchase agreement to acquire 1,000,000 Series A, 1,000,000 Series B, and 1,000,000 Series C Preferred Shares at
The footnotes state he will also acquire, at a later closing following stockholder approval, 1,000,000 Series D and 1,000,000 Series E Preferred Shares at
After this stockholder approval, each First Closing Share will be convertible into 9 ordinary shares and each Second Closing Share into 225 ordinary shares at Lazar’s option for no additional consideration. The filing notes that no ordinary shares are currently beneficially owned and that each class of preferred stock is perpetual with no expiration date.
MAINZ BIOMED N.V. director David E. Lazar filed an initial ownership report on Form 3. The filing shows he currently holds no beneficial ownership of the company’s ordinary shares, as explicitly stated in the accompanying footnote.
Caragol William J reported acquisition or exercise transactions in this Form 4 filing.
MAINZ BIOMED N.V. Chief Financial Officer William J. Caragol received a grant of 290,000 Ordinary Shares on February 13, 2026 as an equity award. The shares were granted at a price of $0.00 per share under the Mainz Biomed N.V. 2025 Omnibus Incentive Plan, with no cash consideration paid.
Following this award, Caragol directly owns a total of 367,899 Ordinary Shares. A separate footnote notes that 77,899 employee stock options were previously granted and reported on a Form 3 filed January 26, 2026.
Dreismann Heinrich reported acquisition or exercise transactions in this Form 4 filing.
Mainz Biomed N.V. director Heinrich Dreismann was granted 45,000 Ordinary Shares on
Following this equity grant, Dreismann directly owns 64,700 Ordinary Shares. A separate footnote notes that 19,700 employee stock options were previously granted and reported on a Form 3 filed on
Tibbitts Gregory J reported acquisition or exercise transactions in this Form 4 filing.
Mainz Biomed N.V. director Gregory J. Tibbitts reported an equity award of 45,000 Ordinary Shares on
Following this grant, Tibbitts beneficially owned a total of 55,875 Ordinary Shares. In a related footnote, the company notes that 10,875 employee stock options had previously been granted and were reported earlier on a Form 3 filed on
MAINZ BIOMED N.V. reported that Chief Executive Officer Guido Baechler acquired 440,000 Ordinary Shares on February 13, 2026 through a grant of restricted shares under the Mainz Biomed N.V. 2025 Omnibus Incentive Plan, with no cash consideration paid. Following this equity award, his directly held Ordinary Shares increased to 605,058. A footnote adds that 6,362 Ordinary Shares and 158,696 employee stock options had been granted earlier and were previously reported on a prior Form 3.
Mainz Biomed N.V. director Hans Hekland reported his existing equity interests with no buy or sell transactions. He directly holds 45,000 Ordinary Shares and several Employee Stock Options (Right to Buy), including positions with 10,000, 625, 250 and 125 underlying shares following the reported holdings.
One option grant vested 50% on 03/04/2025, with the remaining 25% tranches scheduled to vest on 03/24/2026 and 03/04/2027, while another option position is fully vested.
MAINZ BIOMED N.V. Schedule 13G/A amendment shows Armistice Capital, LLC and Steven Boyd reporting beneficial ownership of 435,128 ordinary shares, equal to 4.99% of the class. The filing is a joint statement amendment dated February 17, 2026.
The filing states Armistice Capital is investment manager to Armistice Capital Master Fund Ltd., the direct holder of the shares, and that the Master Fund has the right to receive proceeds or dividends; the Master Fund disclaims beneficial ownership arising solely from the investment management agreement.
Mainz Biomed N.V. entered into a private placement with investor David Lazar for 6.0 USD million of convertible non-redeemable preferred stock, funded in two tranches of 3.0 USD million each. The first 3.0 USD million closed at 1.00 USD per preferred share; the second 3.0 USD million is expected after stockholder approvals at 1.50 USD per preferred share.
The preferred shares are highly dilutive: upon full conversion after required approvals, the First Closing Shares would represent about 55.4% and the Second Closing Shares about 90.2% of issued and outstanding ordinary shares on a fully diluted basis, or roughly 95.6% combined. Until conversion approval, a 19.99% beneficial ownership cap applies.
Net proceeds are earmarked for operations, working capital, and addressing liabilities. The company plans to focus on its U.S. pancreatic cancer detection program, explore sales of colorectal cancer screening assets, and wind down its German subsidiary. David Lazar was appointed Chair of the Board, and settlement agreements with certain officers and directors contemplate about 1.9 USD million of aggregate payments upon the final closing.
Mainz Biomed N.V. disclosed that it has completed share sales under a prospectus supplement tied to its equity distribution agreement with Maxim Group LLC. From January 5, 2026 through January 23, 2026, the company sold 1,735,194 ordinary shares on Nasdaq, generating aggregate gross proceeds of $2,152,822.40 before commissions and expenses.
The prospectus supplement allowed sales of ordinary shares up to an aggregate maximum offering price of $2,152,823, which has now been fully utilized. The broader equity distribution agreement, which permits offerings of up to $10,000,000 of ordinary shares, remains available for future sales, subject to market conditions and other factors.